Technology | Stents Bare Metal | December 09, 2015

Medinol Begins U.S. Commercialization of New Coronary Stent

NIRxcell CoCr Stent System first product launched from new U.S. headquarters

December 9, 2015 — Medinol U.S. recently opened their commercial business in Parsippany, New Jersey, followed by the launch of the NIRxcell CoCr Stent System.

During the recent 2015 Transcatheter Cardiovascular Therapeutics (TCT) meeting in San Francisco, Medinol Ltd. hosted a satellite symposium, "The BioNIR eDES: The Role of Uniformity in Stent Design to Minimize Restenosis", where a physician panel discussed the key attributes of the NIRxcell System and the Medinol eDES Coronary Stent System (in trials, not FDA/CE Mark approved). Physician faculty included David E. Kandzari, M.D., Piedmont Heart Institute; Jim Zidar, M.D., North Carolina Heart and Vascular; Rajiv Jauhar, M.D., North Shore University Medical Center; Peter Smits, M.D., Maasstad Ziekenhuis, Rotterdam, the Netherlands; and Shmuel Banai, M.D., The Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. Discussion highlighted key product features and emphasized the design of the BIONICS/NIREUS clinical trials that have recently completed enrollment. 

Kandzari commented, "The delivery system is unlike in any other product on the market" and Medinol's approach to trial design "was entirely unlike any other pivotal trial as it included a 'more comers' patient population."

On an annual basis, approximately 800,000 patients undergo coronary stenting procedures in the United States. Healthcare providers continue to look for novel, effective and efficient solutions to treat their patients.

For more information: www.medinol.com

Related Content

Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Overlay Init